Inhalok Airmaster (Fluticasone Propionate, Salmeterol)

Inhalok Airmaster, an inhaled corticosteroid/long‑acting β2‑agonist (ICS/LABA) combination, is used in the management of obstructive airway diseases.

• Asthma: provides anti‑inflammatory action and prolonged bronchodilation, leading to better symptom control, fewer nighttime awakenings and reduced need for rescue inhaler use.
• COPD: delivers combined anti‑inflammatory and bronchodilator effects that lessen dyspnea, improve exercise tolerance and lower the incidence of moderate to severe exacerbations.
• Chronic bronchitis (a COPD phenotype): helps maintain airway patency, reduces sputum volume and frequency of cough, contributing to overall lung‑function stability.

• Fluticasone propionate binds to intracellular glucocorticoid receptors, modulating gene transcription to suppress pro‑inflammatory cytokines, chemokines and cellular infiltration in the airway mucosa. Salmeterol selectively stimulates β2‑adrenergic receptors on bronchial smooth muscle, activating adenylate cyclase and increasing cyclic AMP, which produces sustained relaxation of airway smooth muscle. The combined actions result in reduced airway inflammation together with long‑lasting bronchodilation.

The most frequently reported adverse reactions with Inhalok Airmaster involve the local airways, while rare but serious events may occur.

Common Side Effects

• Throat irritation or soreness, often transient after inhalation.
• Hoarseness or voice change due to local steroid effect on vocal cords.
• Oral candidiasis (thrush), especially if the inhaler is not rinsed after use.
• Headache, mild to moderate intensity, occurring shortly after dosing.

Serious or Rare Side Effects

• Paradoxical bronchospasm, a sudden worsening of breathing that may require emergency treatment.
• Adrenal suppression, possible with long‑term high‑dose therapy, leading to fatigue, nausea or hypotension.
• Severe allergic reactions, including anaphylaxis, characterized by rash, swelling, difficulty breathing or shock.

When prescribing Inhalok Airmaster, clinicians should consider several precautionary measures to ensure safe and effective use.

• Assess inhaler technique: verify patient can use the device correctly to achieve optimal drug delivery.
• Monitor for oral candidiasis: advise regular mouth rinsing and inspection of the oropharynx.
• Use with caution in patients with cardiovascular disease: β2‑agonist may cause tachycardia or palpitations.
• Avoid abrupt discontinuation: tapering may be needed to prevent loss of asthma control.
• Review concomitant medications: consider potential drug interactions that could affect steroid or β2‑agonist levels.
• Store at room temperature: keep the inhaler in its original packaging, protect from moisture and direct heat.

Inhalok Airmaster may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective beta‑blockers (e.g., propranolol) can diminish bronchodilator response and precipitate bronchospasm.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) increase systemic exposure to fluticasone, raising the risk of corticosteroid‑related effects.
• Monoamine oxidase inhibitors (MAOIs) may potentiate cardiovascular side effects of salmeterol.

Moderate Interactions (Monitor Closely)

• Diuretics (e.g., furosemide) can enhance hypokalemia risk associated with β2‑agonist use.
• Theophylline may increase the likelihood of tachyarrhythmias when combined with salmeterol.
• Anticholinergic bronchodilators (e.g., tiotropium) may produce additive anticholinergic effects, requiring clinical monitoring.